SCHEMBL14320583

SCHEMBL14320583

CN1CCN(c2ccc(Nc3nc(-c4ccccc4)nc4cn[nH]c34)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.62
SYK P43405 8/20 0.60
AURKA O14965 2/20 0.55
AURKB Q96GD4 2/20 0.55
ADRA2A P08913 3/20 0.50
ADRA2C P18825 3/20 0.50
ADRA2B P18089 2/20 0.50
KDM1A O60341 1/20 0.50
GLA P06280 1/20 0.50
SLC2A1 P11166 1/20 0.50
RECQL P46063 1/20 0.50
BLM P54132 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALK Q9UM73 1/20 0.50
JAK3 P52333 1/20 0.49
MAP4K1 Q92918 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HTR2A P28223 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320457 0.91 JAK2 (0.52) JAK2SYKAURKAAURKBADRA2A
SCHEMBL14320816 0.90 SYK (0.63) JAK2SYKMAPTMAPK1NPSR1
SCHEMBL14320277 0.90 JAK2 (0.76) JAK2SYKAURKAADRA2AADRA2C
SCHEMBL14320510 0.89 SYK (0.62) JAK2SYKMAPTMAPK1NPSR1
SCHEMBL14320415 0.89 SYK (0.54) JAK2SYKAURKA
SCHEMBL14320869 0.88 SYK (0.75) JAK2SYKMAPTMAPK1NPSR1
SCHEMBL14320440 0.88 JAK2 (0.55) JAK2SYKKDM1AMAPK1HTR2A
SCHEMBL14320792 0.87 JAK2 (0.65) JAK2SYKAURKAAURKBALK
SCHEMBL14320601 0.87 JAK2 (0.49) JAK2SYKAURKAAURKBALK
SCHEMBL14320671 0.87 JAK2 (0.57) JAK2SYKAURKAKDM1AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK JAK2 60/4885SYK 11/4885AURKA 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.